Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $69.01 USD
Change Today -2.64 / -3.68%
Volume 1.9M
As of 8:10 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Todd C. Brady M.D., Ph.D.

Former Board Observer, Esperion Therapeutics, Inc.
AgeTotal Calculated CompensationThis person is connected to 79 board members in 12 different organizations across 13 different industries.

See Board Relationships


Dr. Todd C. Brady, M.D., Ph.D., has been an Advisor to Leader Ventures since 2011. Dr. Brady has been the Chief Executive Officer and President of Aldeyra Therapeutics, Inc. since January 2012. He is a Co-Founder of Phenome Sciences and serves as its Chief Executive Officer. He serves as a Senior Advisor at Solidus Investment Co., Ltd. He served as Principal Financial and Accounting Officer of Aldeyra Therapeutics, Inc. He was an Entrepreneur-In-Residence at Domain Associates, ...

Read Full Background

Corporate Headquarters*

3891 Ranchero Drive
Ann Arbor, Michigan 48108

United States

Phone: 734-887-3903
Fax: --

Board Members Memberships*

Board Observer
Board Observer
Board Observer
Chief Executive Officer, President and Director
Director, Chairman of Nominating & Corporate Governance Committee and Member of Compensation Committee


MD 1999
Duke University Medical Center
BA 1993
Dartmouth College
PhD 1998
Duke University
PhD 1998
The Graduate School, Duke University

Other Affiliations*

Annual Compensation*

Total Annual Compensation$377,500

Stock Options*

All Other Compensation$9,013
Exercisable Options153,005
Unexercisable Options260,149
Total Number of Options445,168

Total Compensation*

Total Annual Cash Compensation$620,513
Total Short Term Compensation$377,500
Other Long Term Compensation$9,013
Total Calculated Compensation$1,075,384
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ESPR:US $69.01 USD -2.64


There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ESPERION THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at